同种异体ICAM-1的缺失可减弱同种抗原特异性T细胞致敏,但不会减弱已致敏T细胞向移植物的迁移,从而介导急性排斥反应。
Absence of allograft ICAM-1 attenuates alloantigen-specific T cell priming, but not primed T cell trafficking into the graft, to mediate acute rejection.
作者信息
Zhang Qi-Wei, Kish Danielle D, Fairchild Robert L
机构信息
Department of Immunology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
出版信息
J Immunol. 2003 Jun 1;170(11):5530-7. doi: 10.4049/jimmunol.170.11.5530.
The expression and function of ICAM-1 are critical components in the initiation and elicitation of many T cell-mediated responses. Whether ICAM-1 expression is required on the T cells or on the APC during T cell priming remains unclear. To address this issue in alloantigen-specific T cell activation, the priming and function of T cells in response to heart allografts from MHC-mismatched wild-type vs ICAM-1(-/-) donors were tested. Wild-type C57BL/6 (H-2(b)) heart allografts were rejected by A/J (H-2(a)) recipients on days 7-9, whereas B6.ICAM-1(-/-) allografts survived until days 18-23 post-transplant. On day 7 post-transplant, infiltrating macrophages and CD4(+) and CD8(+) T cells in the ICAM-1(-/-) allografts were 20-30% those observed in the wild-type allografts. ELISPOT analyses indicated that the number of alloantigen-specific T cells producing IFN-gamma from recipients of ICAM-1-deficient grafts was 60% lower than that from recipients of wild-type allografts. On day 16 post-transplant, these numbers did not markedly increase in ICAM-1-deficient allograft recipients. Consistent with the reduced priming of alloreactive T cells, isolated dendritic cells from ICAM-1(-/-) mice stimulated allogeneic T cell proliferation poorly compared with wild-type dendritic cells. When A/J mice were primed with wild-type dendritic cells and then received wild-type or ICAM-1-deficient heart allografts 3 days later, the primed recipients rejected the wild-type and ICAM-1(-/-) allografts on days 5-6 post-transplant. These results indicate that optimal priming of alloreactive T cells requires allograft expression of ICAM-1, but, once primed, recipient T cell infiltration into the allograft is independent of graft ICAM-1 expression.
ICAM-1的表达和功能是许多T细胞介导反应的起始和激发过程中的关键组成部分。在T细胞致敏过程中,ICAM-1的表达是需要在T细胞上还是在抗原呈递细胞(APC)上尚不清楚。为了在同种异体抗原特异性T细胞激活中解决这个问题,测试了来自MHC不匹配的野生型与ICAM-1(-/-)供体的心脏同种异体移植中T细胞的致敏和功能。野生型C57BL/6(H-2(b))心脏同种异体移植在第7-9天被A/J(H-2(a))受体排斥,而B6.ICAM-1(-/-)同种异体移植在移植后存活至第18-23天。移植后第7天,ICAM-1(-/-)同种异体移植中浸润的巨噬细胞以及CD4(+)和CD8(+) T细胞是野生型同种异体移植中观察到的细胞数量的20%-30%。酶联免疫斑点(ELISPOT)分析表明,来自ICAM-1缺陷移植物受体的产生γ干扰素的同种异体抗原特异性T细胞数量比野生型同种异体移植受体的低60%。移植后第16天,ICAM-1缺陷同种异体移植受体中的这些细胞数量没有明显增加。与同种异体反应性T细胞致敏减少一致,与野生型树突状细胞相比,来自ICAM-1(-/-)小鼠的分离树突状细胞刺激同种异体T细胞增殖的能力较差。当用野生型树突状细胞致敏A/J小鼠,然后在3天后接受野生型或ICAM-1缺陷的心脏同种异体移植时,致敏受体在移植后第5-6天排斥野生型和ICAM-1(-/-)同种异体移植。这些结果表明,同种异体反应性T细胞的最佳致敏需要同种异体移植表达ICAM-1,但是,一旦致敏,受体T细胞浸润到同种异体移植中则与移植的ICAM-1表达无关。